Michiel M. Smeenk

Statistics

Publications

Citations

109

H-Index

Active since

2015

Affiliations

Leiden University Medical Center(Current)

Michiel M. Smeenk is an author at Leiden University Medical Center specializing in monoclonal antibodies in oncology, antibody-drug conjugates, and oncology.

ORCID

Publications per year

2015–2025

Publications

ImmunoPET with Anti-Mesothelin Antibody in Patients with Pancreatic and Ovarian Cancer before Anti-Mesothelin Antibody–Drug Conjugate Treatment

Laetitia E. Lamberts, C. Willemien Menke‐van der Houven van Oordt, Eva J. ter Weele et al. · Clinical Cancer Research · 2015 · 98 citations

Medicine, Cancer Biology, Oncology +17

Pembrolizumab hybrid dosing is non-inferior to flat dosing in advanced non-small cell lung cancer: a real-world, retrospective bicenter cohort study

Michiel M. Smeenk, Vincent van der Noort, Jeroen J. M. A. Hendrikx et al. · Journal for ImmunoTherapy of Cancer · 2025 · 11 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

1–2 of 2